Effectiveness of Hospital Pharmacist Interventions for COPD Patients: A Systematic Literature Review and Logic Model

References

• Soriano JB, Kendrick PJ, Paulson KR. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Li X, Cao X. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020;368:34.
   Google Scholar
• World Health Organization. Chronic respiratory diseases: burden of COPD. Available from: https://www.who.int/respiratory/copd/burden/. Accessed April 17, 2020.
   Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Marton J. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med. 2008;102(9):1248–1256. doi:10.1016/j.rmed.2008.04.009
   PubMed Web of Science ®Google Scholar
• Li M, Wang F. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. Int J Chron Obstruct Pulmon Dis. 2018;13:3349. doi:10.2147/COPD.S175143
   PubMed Web of Science ®Google Scholar
• Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM. COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis. 2016;11:697. doi:10.2147/COPD.S100250
   PubMed Web of Science ®Google Scholar
• Thomas M, Radwan A. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2014;11(3):300–309.
   PubMedGoogle Scholar
• Xu X, Knight T. Patient characteristics, health resource utilization (HRU) and treatment costs of chronic obstructive pulmonary disease (COPD) patients treated in hospital facilities for exacerbations. In: B45. Exacerbations of COPD: Prevention, Treatment and Outcomes. American Thoracic Society; 2012:A3047.
   Google Scholar
• Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613–620. doi:10.1016/S0140-6736(04)16855-4
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141. doi:10.3109/15412555.2011.650239
   PubMedGoogle Scholar
• Liang L, Li C, Shen Y, et al. Long-term trends in hospitalization and outcomes in adult patients with exacerbation of chronic obstructive pulmonary disease in Beijing, China, from 2008 to 2017. Int J Chron Obstruct Pulmon Dis. 2020;15:1155. doi:10.2147/COPD.S238006
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771. doi:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Overbeek JA, Penning-van Beest FJA, Balp MM, et al. Burden of exacerbations in patients with moderate to very severe COPD in the Netherlands: a real-life study. COPD. 2015;12(2):132–143. doi:10.3109/15412555.2014.898053
   PubMedGoogle Scholar
• Mohammed MA, Moles RJ, Chen TF. Impact of pharmaceutical care interventions on health-related quality-of-life outcomes: a systematic review and meta-analysis. Ann Pharmacother. 2016;50(10):862–881. doi:10.1177/1060028016656016
   PubMed Web of Science ®Google Scholar
• Juanes A, Garin N, Mangues MA, et al. Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial. Eur J Hosp Pharm. 2018;25(5):274–280. doi:10.1136/ejhpharm-2016-001055
   PubMedGoogle Scholar
• Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS One. 2017;12(2):e0170495. doi:10.1371/journal.pone.0170495
   PubMed Web of Science ®Google Scholar
• Smith AL, Palmer V, Farhat N, et al. Hospital-based clinical pharmacy services to improve ambulatory management of chronic obstructive pulmonary disease. J Pharm Technol. 2017;33(1):8–14. doi:10.1177/8755122516675635
   Web of Science ®Google Scholar
• Gentene AJ, Guido MR, Woolf B, et al. Multidisciplinary team utilizing pharmacists in multimodal, bundled care reduce chronic obstructive pulmonary disease hospital readmission rates. J Pharm Pract. 2021;34(1):110–116. doi:10.1177/0897190019889440
   PubMed Web of Science ®Google Scholar
• Van der Molen T, van Boven JFM, Maguire T, et al. Optimizing identification and management of COPD patients–reviewing the role of the community pharmacist. Br J Clin Pharmacol. 2017;83(1):192–201. doi:10.1111/bcp.13087
   PubMed Web of Science ®Google Scholar
• Hu Y, Yao D, Ung COL, et al. Promoting community pharmacy practice for Chronic Obstructive Pulmonary Disease (COPD) management: a systematic review and logic model. Int J Chron Obstruct Pulmon Dis. 2020;15:1863. doi:10.2147/COPD.S254477
   PubMed Web of Science ®Google Scholar
• Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 3rd ed. European Respiratory Society; 2021. Available from: firsnet.org/images/publications/FIRS_Master_09202021.pdf. Accessed September 22, 2021.
   Google Scholar
• Page MJ, Moher D. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:23.
   Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28–55. doi:10.1016/j.ijsu.2011.10.001
   PubMed Web of Science ®Google Scholar
• De Tullio PL, Kirking DM, Arslanian C, et al. Compliance measure development and assessment of theophylline therapy in ambulatory patients. J Clin Pharm Ther. 1987;12(1):19–26.
   PubMed Web of Science ®Google Scholar
• Khdour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy‐led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68(4):588–598. doi:10.1111/j.1365-2125.2009.03493.x
   PubMed Web of Science ®Google Scholar
• Shen J, Sun Q, Zhou X, et al. Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm. 2011;33(6):929–933. doi:10.1007/s11096-011-9577-z
   PubMed Web of Science ®Google Scholar
• Jarab AS, AlQudah SG, Khdour M, et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm. 2012;34(1):53–62. doi:10.1007/s11096-011-9585-z
   PubMed Web of Science ®Google Scholar
• Wei L, Li J, Luo H, et al. Effects of pharmaceutical care on drug compliance of patients with chronic obstructive pulmonary disease in stable phase. China Pharm. 2013;24(14):1316–1318.
   Google Scholar
• Wei L, Yang X, Li J, et al. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. J Thorac Dis. 2014;6(6):656. doi:10.3978/j.issn.2072-1439.2014.06.20
   PubMed Web of Science ®Google Scholar
• Farris KB, Carter BL, Xu Y, et al. Effect of a care transition intervention by pharmacists: an RCT. BMC Health Serv Res. 2014;14(1):1–13. doi:10.1186/1472-6963-14-406
   PubMed Web of Science ®Google Scholar
• Wei B, Tang L, Deng B, et al. Comparative analysis of antibacterial drugs therapy for COPD inpatients. Chin Pharm. 2014;25(34):3172–3174.
   Google Scholar
• Yan Y, Jiang X, Ting X. The clinical therapeutic effect of pharmaceutical care on old patients with chronic obstructive pulmonary disease. Chin J Hosp Pharm. 2014;34(06):489–491.
   Google Scholar
• Wang Y, Yu L, Cui H. Effect of pharmaceutical care on the efficacy of senior patients with Chronic Obstructive Pulmonary. Chin Pharmacist. 2015;2015:1760–1762.
   Google Scholar
• Lin Q, Dai W, Zheng B, et al. Study on the application of oxygen-driven aerosol inhalation in chronic obstructive pulmonary disease patients and pharmaceutical care in our hospital. Chin Pharm. 2015;26;02:276–278.
   Google Scholar
• Suhaj A, Manu MK, Unnikrishnan MK, et al. Effectiveness of clinical pharmacist intervention on health‐related quality of life in chronic obstructive pulmonary disorder patients–a randomized controlled study. J Clin Pharm Ther. 2016;41(1):78–83. doi:10.1111/jcpt.12353
   PubMed Web of Science ®Google Scholar
• Xin C, Xia Z, Jiang C, et al. The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: a randomized controlled study. Patient Prefer Adherence. 2016;10:1197. doi:10.2147/PPA.S110167
   PubMed Web of Science ®Google Scholar
• Qin Q, Chen R, Zhang Y, et al. Clinical evaluation and implement of grading pharmaceutical care on patients with asthma and COPD. Chin Pharmaceut J. 2017;2017:1460–1464.
   Google Scholar
• Zhang L, Dong H. Evaluation of intervention effects of standardized pharmaceutical care on clinical treatment of AECO-PD patients. Chin Pharm. 2017;32:2847–2851.
   Google Scholar
• Abdulsalim S, Unnikrishnan MK, Manu MK, et al. Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Res Soc Admin Pharm. 2018;14(10):909–914. doi:10.1016/j.sapharm.2017.10.008
   PubMed Web of Science ®Google Scholar
• Chen R, Zhou L, Qin Q, et al. Study on practice and effect of SIMPLE pharmaceutical care mode in Chronic Disease Management of Bronchial asthma and COPD patients. Chin Pharm. 2018;32:1400–1403.
   Google Scholar
• Song Z, Zheng C, Xing S, et al. Integrated pharmaceutical care for asthma-COPD overlap syndrome patients. Herald Med. 2018;2018:319–322.
   Google Scholar
• Bloodworth LS, Malinowski SS, Lirette ST, et al. Pharmacist linkage in care transitions: from academic medical center to community. J Am Pharm Assoc. 2019;59(6):896–904. doi:10.1016/j.japh.2019.08.011
   Google Scholar
• Chen J, Lei M, Li S, et al. Evaluating and analyzing the use of inhalation devices in chronic obstructive pulmonary disease patients. Chin J Clin Pharmacol. 2019;35;11:1179–1182.
   Google Scholar
• Li Z, Zhong H, Ouyang A. Pharmaceutical intervention in evaluation of clinical pathway for patients with chronic obstructive pulmonary disease effect. Chin J Hosp Pharm. 2019;39(05):525–527+540.
   Google Scholar
• Yang X, Zhu Q. Application effect of clinical pharmacist developing pharmaceutical service in patients with Chronic Obstructive Pulmonary Disease. J Chongqing Univ Technol. 2019;33(03):184–188.
   Google Scholar
• Abdulsalim S, Unnikrishnan MK, Manu MK, et al. Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India. Pharmacoeconomics-Open. 2020;4(2):331–342. doi:10.1007/s41669-019-0172-x
   PubMed Web of Science ®Google Scholar
• Wang W, Xu T, Qin Q, et al. Effect of a multidimensional pharmaceutical care intervention on inhalation technique in patients with asthma and COPD. Can Respir J. 2020;2020:1–10. doi:10.1155/2020/8572636
   Web of Science ®Google Scholar
• Wang Y, Wu Q, Chen H, et al. Evaluation of the effectiveness of medication management services in patients with chronic obstructive pulmonary disease. Chin J Hosp Pharm. 2020;40(23):2453–2458.
   Google Scholar
• Wang W, Zhou L, Chen R. Practice and exploration of characteristic pharmaceutical care model in patients with asthma and Chronic Obstructive Pulmonary Disease. Herald Med. 2020;39(12):1735–1741.
   Google Scholar
• Prasungriyo N, Sooksai N. Effect of pharmacy counseling on readmissions in patients with acute exacerbations of COPD: a randomized controlled trial. J Health Sci Med Res. 2021;39(6):467–479.
   Google Scholar
• Liu M, Liu J, Geng Z, et al. Evaluation of outcomes of medication therapy management (MTM) services for patients with chronic obstructive pulmonary disease (COPD). Pak J Med Sci. 2021;37(7):1832–1836. doi:10.12669/pjms.37.7.4518
   PubMed Web of Science ®Google Scholar
• Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available from: https://www.nice.org.uk/guidance/ng115. Accessed July 26, 2019.
   Google Scholar
• Detoni KB, Oliveira IV, Nascimento MMG, Caux TR, Alves MR, Ramalho-de-oliveira D. Impact of a medication therapy management service on the clinical status of patients with chronic obstructive pulmonary disease. Int J Clin Pharm. 2017;39(1):95–103. doi:10.1007/s11096-016-0402-6
   PubMed Web of Science ®Google Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;21:533–543.
   Google Scholar
• Global strategy for prevention, diagnosis and management of COPD: 2022 Report. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed October 12, 2022.
   Google Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794. doi:10.1183/13993003.01794-2016
   PubMed Web of Science ®Google Scholar
• Ding B, Siddiqui S, DePietro M, Petersson G, Martin UJ. inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: a simulated-use study. Chron Respir Dis. 2018;16:1479972318787914. doi:10.1177/1479972318787914
   Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.005
   PubMed Web of Science ®Google Scholar
• Hodder R. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J Chron Obstruct Pulmon Dis. 2009;107:381. doi:10.2147/COPD.S3391
   Google Scholar
• Eisenhower C. Impact of pharmacist-conducted medication reconciliation at discharge on readmissions of elderly patients with COPD. Ann Pharmacother. 2014;48(2):203–208. doi:10.1177/1060028013512277
   PubMed Web of Science ®Google Scholar
• Hudd TR. Emerging role of pharmacists in managing patients with chronic obstructive pulmonary disease. Eur Respir J. 2020;77(19):1625–1630. doi:10.1093/ajhp/zxaa216
   Web of Science ®Google Scholar
• Global initiative for Chronic Obstructive Lung Disease. GOLD 2020 guidelines. Available from: https://goldcopd.org/. Accessed March 12, 2020.
   Google Scholar
• Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR. A tailored intervention to support pharmacy-based counseling for smoking cessation. Nicotine Tob Res. 2010;12(3):217–225. doi:10.1093/ntr/ntp197
   PubMed Web of Science ®Google Scholar
• Adams AJ, Hudmon KS. Pharmacist prescriptive authority for smoking cessation medications in the United States. J Am Pharm Assoc. 2018;58(3):253–257. doi:10.1016/j.japh.2017.12.015
   Google Scholar
• Transitions of care. Available from: https://apps.who.int/iris/bitstream/handle/10665/252272/9789241511599-eng.pdf. Accessed October 12, 2022.
   Google Scholar
• Kirwin J, Canales AE, Bentley ML; American College of Clinical Pharmacy. Process indicators of quality clinical pharmacy services during transitions of care. Pharmacotherapy. 2012;32(11):e338–e347. doi:10.1002/phar.1214
   PubMed Web of Science ®Google Scholar
• Bethishou L, Herzik K, Fang N, Abdo C, Tomaszewski DM. The impact of the pharmacist on continuity of care during transitions of care: a systematic review. J Am Pharm Assoc. 2020;60(1):163–177. doi:10.1016/j.japh.2019.06.020
   Google Scholar
• Ensing HT, Koster ES, Dubero DJ, van Dooren AA, Bouvy ML. Collaboration between hospital and community pharmacists to address drug-related problems: the HomeCoMe-program. Res Soc Admin Pharm. 2019;15(3):267–278. doi:10.1016/j.sapharm.2018.05.001
   PubMed Web of Science ®Google Scholar
• Li J, Young R, Williams MV. Optimizing transitions of care to reduce rehospitalizations. Cleve Clin J Med. 2014;81(5):312–320. doi:10.3949/ccjm.81a.13106
   PubMed Web of Science ®Google Scholar
• Thoma MM. ASHP statement on the pharmacist’s role in medication reconciliation. Eur Respir J. 2013;70(5):453–457.
   Google Scholar
• Hwang AY, Gums TH, Gums JG. The benefits of physician-pharmacist collaboration. J Fam Pract. 2017;66(12):E1–E8.
   PubMed Web of Science ®Google Scholar
• NHS. Treatment - Chronic obstructive pulmonary disease (COPD). Available from: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/treatment/#:~:text=Pulmonary%20rehabilitation%20is%20a%20specialised,self%2Dconfidence%20and%20emotional%20wellbeing. Accessed October 12, 2022.
   Google Scholar
• Arabyat RM, Raisch DW, Bakhireva L. Influenza vaccination for patients with chronic obstructive pulmonary disease: implications for pharmacists. Res Soc Admin Pharm. 2018;14(2):162–169. doi:10.1016/j.sapharm.2017.02.010
   PubMed Web of Science ®Google Scholar